Clinical trials: Gastrointestinal Neoplasms
Endoscopic Submucosal Dissection
Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom
Multicentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.
- Trial name
- ESDUK (NCT03039309)
- Testing
- Endoscopic Submucosal Dissection
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Gastric Cancer
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy.
- Trial name
- NCT05871099
- Testing
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- China
- Volunteers
- 616 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Colorectal Neoplasms
Diagnostic Performance Assessment of Qualitative Ifobt and Quantitative Ifobt for Advanced Neoplastic
In Argentina, there is vast experience in qualitative iFOBT population screening that is part of the CRC Prevention and Early Detection National Program. The screening's cut-off point is at 50 ng/mL buffer.
- Trial name
- NCT04831632
- Testing
- quantitative and qualitative iFOBTs
- Where
- Argentina
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- CECILIA CURVALE
Gastric Cancer
Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer
RATIONALE: Neoadjuvant chemotherapy has been proved effective for locally advanced gastric cancer, yet the best pattern of response evaluation remain unknown.
- Trial name
- NCT02179463
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University
Rectal Cancer
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
Irinotecan is one of effective drugs for colorectal cancer. In neoadjuvant chemoradiotherapy (CRT), Irinotecan is prescribed in a low dose of 50mg/m2/week because of toxicity.
- Trial name
- NCT01474187
- Testing
- Irinotecan, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Mindfulness, Colon Cancer
Targeting Chronic Stress for Reducing Risk Factors for Colorectal Cancer
Many neighborhoods in Chicago experience daily exposure to stressors including economic inopportunity and violent crime in public spaces.
- Conditions
- Mindfulness, Colon Cancer, Females
- Trial name
- MindCRC (NCT06323421)
- Testing
- Mindfulness
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Ovarian Neoplasms, Ovarian Diseases
89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
The purpose of this multicenter imaging sub study is to evaluate the biodistribution and organ pharmacokinetics of 89Zr-MMOT0530A in patients with unresectable pancreatic or platinum-resistant ovarian cancer.
- Conditions
- Ovarian Neoplasms, Ovarian Diseases, Adnexal Diseases, Pancreatic Neoplasms
- Trial name
- MMOT (NCT01832116)
- Testing
- 89Zr-MMOT0530A
- Where
- 2 sites in Netherlands
- Volunteers
- 11 people
- Sponsor
- University Medical Center Groningen
Colorectal Cancer, Polyps
Vitamin D/Calcium Polyp Prevention Study
Extensive experimental and observational data suggest that intake of calcium and of vitamin D exert protective effects on colorectal neoplasia.
- Conditions
- Colorectal Cancer, Polyps, Adenomas
- Trial name
- NCT00153816
- Testing
- Calcium Carbonate, Vitamin D3
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 2,813 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colonic Neoplasms, Colorectal Neoplasms
Performance and Evaluation for CT Colonography Screening
Colorectal cancer (CRC) is an important United Kingdom healthcare issue affecting 1 in 20 individuals, half of whom will die from the disease.
- Trial name
- PERFECTS (NCT02892721)
- Testing
- Training with feedback
- Where
- United Kingdom
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- London North West Healthcare NHS Trust
Colorectal Cancer, Type 2 Diabetes
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
The goal of this observation study is to deliver an education program designed to increase knowledge of colorectal cancer prevention and nutrition education in minorities with Type 2 diabetes.
- Trial name
- NCT05765214
- Testing
- Intervention Group (IG)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Gastric Cancer
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer.
- Trial name
- CURE (NCT04576858)
- Testing
- Circulating tumor DNA
- Where
- Denmark
- Volunteers
- 1,950 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HepatoCellular Carcinoma, Cirrhosis
Mutational Landscape in Hepatocellular Carcinoma
The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of…
- Trial name
- MUTHEC (NCT03071458)
- Where
- France
- Volunteers
- 808 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers.
- Conditions
- Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03602885
- Testing
- Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor…
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT07132008
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 94 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Cryptogenic Hypertransaminasemia
Patients With Cryptogenic Hypertransaminasemia
Persistent unexplained elevation of serum aminotransferases (ALT and AST) remains undiagnosed in a subset of patients despite a comprehensive diagnostic work-up.
- Trial name
- LIFT (NCT07834125)
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations
This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases, Pancreatic Elastase 1, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06041009
- Testing
- Pancreatic elastase-1 in blood serum
- Where
- China
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Colorectal Neoplasms, Adenoma Detection Rate
Impact of Proximal Colon Retroflexion in Colorectal Cancer Screening Programme
Colorectal cancer (CRC) is the most common tumor and the second leading cause of death in the Western world. The decrease in incidence and mortality by CRC in the population undergoing screening has been observed.
- Trial name
- NCT03041532
- Testing
- Proximal retroflexion, Frontal view
- Where
- Spain
- Volunteers
- 692 people
- Sponsor
- Hospital del Rio Hortega
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital